Innoviva, Inc. – NASDAQ:INVA
Innoviva stock price today
$20.29
+2.73
+15.61%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Innoviva stock price monthly change
+4.90%
month
Innoviva stock price quarterly change
+4.90%
quarter
Innoviva stock price yearly change
+7.87%
year
Innoviva key metrics
Market Cap | 1.11B |
Enterprise value | 1.07B |
P/E | 4.9 |
EV/Sales | 3.23 |
EV/EBITDA | 3.42 |
Price/Sales | 2.48 |
Price/Book | 1.45 |
PEG ratio | -0.93 |
EPS | 2.82 |
Revenue | 318.47M |
EBITDA | 152.89M |
Income | 181.38M |
Revenue Q/Q | 6.00% |
Revenue Y/Y | 0.26% |
Profit margin | 64.56% |
Oper. margin | 62.47% |
Gross margin | 36% |
EBIT margin | 62.47% |
EBITDA margin | 48.01% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInnoviva stock price history
Innoviva stock forecast
Innoviva financial statements
| Jun 2023 | 80.99M | 1.28M | 1.58% |
|---|---|---|---|
| Sep 2023 | 67.25M | 82.04M | 121.99% |
| Dec 2023 | 89.27M | 61.53M | 68.93% |
| Mar 2024 | 80.95M | 36.53M | 45.13% |
| 2025 | 319.48M | 36.43M | 11.4% |
|---|---|---|---|
| 2026 | 345.27M | 42.02M | 12.17% |
| 2027 | 370.2M | 48.34M | 13.06% |
| 2028 | 450.8M | 66.37M | 14.72% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 1118241000 | 563.15M | 50.36% |
|---|---|---|---|
| Sep 2023 | 1188104000 | 560.61M | 47.19% |
| Dec 2023 | 1243507000 | 568.55M | 45.72% |
| Mar 2024 | 1267612000 | 563.93M | 44.49% |
| Jun 2023 | 38.18M | -17.78M | -9.20M |
|---|---|---|---|
| Sep 2023 | 43.94M | -25.88M | -11.08M |
| Dec 2023 | 33.25M | -5.15M | -14.58M |
| Mar 2024 | 37.04M | -43.03M | -9.16M |
Innoviva alternative data
| Aug 2023 | 101 |
|---|---|
| Sep 2023 | 101 |
| Oct 2023 | 101 |
| Nov 2023 | 101 |
| Dec 2023 | 101 |
| Jan 2024 | 101 |
| Feb 2024 | 101 |
| Mar 2024 | 112 |
| Apr 2024 | 112 |
| May 2024 | 112 |
| Jun 2024 | 112 |
| Jul 2024 | 112 |
Innoviva other data
76.39%
-7.47%
of INVA is owned by hedge funds
190
-23
73.06M
-5.53M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 3000 | 0 |
| May 2023 | 596000 | 0 |
| Jun 2023 | 77000 | 0 |
| Nov 2023 | 0 | 10994 |
| Quarter | Transcript |
|---|---|
| Q3 2017 25 Oct 2017 | Q3 2017 Earnings Call Transcript |
| Q2 2017 26 Jul 2017 | Q2 2017 Earnings Call Transcript |
| Q1 2017 27 Apr 2017 | Q1 2017 Earnings Call Transcript |
| Q4 2016 10 Feb 2017 | Q4 2016 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Ms. Marianne Zhen CPA (1969) Chief Accounting Officer | $433,870 |
Mr. Pavel Raifeld C.F.A. (1984) Chief Executive Officer | $373,970 |
-
What's the price of Innoviva stock today?
One share of Innoviva stock can currently be purchased for approximately $20.29.
-
When is Innoviva's next earnings date?
Unfortunately, Innoviva's (INVA) next earnings date is currently unknown.
-
Does Innoviva pay dividends?
No, Innoviva does not pay dividends.
-
How much money does Innoviva make?
Innoviva has a market capitalization of 1.11B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.3% to 310.46M US dollars.
-
What is Innoviva's stock symbol?
Innoviva, Inc. is traded on the NASDAQ under the ticker symbol "INVA".
-
What is Innoviva's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Innoviva?
Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Innoviva's key executives?
Innoviva's management team includes the following people:
- Ms. Marianne Zhen CPA Chief Accounting Officer(age: 56, pay: $433,870)
- Mr. Pavel Raifeld C.F.A. Chief Executive Officer(age: 41, pay: $373,970)
-
How many employees does Innoviva have?
As Jul 2024, Innoviva employs 112 workers.
-
When Innoviva went public?
Innoviva, Inc. is publicly traded company for more then 20 years since IPO on 5 Oct 2004.
-
What is Innoviva's official website?
The official website for Innoviva is inva.com.
-
Where are Innoviva's headquarters?
Innoviva is headquartered at 1350 Old Bayshore Highway, Burlingame, CA.
-
How can i contact Innoviva?
Innoviva's mailing address is 1350 Old Bayshore Highway, Burlingame, CA and company can be reached via phone at +65 02389600.
Innoviva company profile:
Innoviva, Inc.
inva.comExchange:
NASDAQ
Full time employees:
112
Industry:
Biotechnology
Sector:
Healthcare
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
1350 Old Bayshore Highway
Burlingame, CA 94010
Burlingame, CA 94010
CIK: 0001080014
ISIN: US45781M1018
CUSIP: 45781M101
